Comparative Pharmacology
Head-to-head clinical analysis: FLUTEX versus PSORCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTEX versus PSORCON.
FLUTEX vs PSORCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flutamide is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone (DHT) to androgen receptors in target tissues, thereby blocking the androgenic effects.
Psorcon (diflorasone diacetate) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. It inhibits the release of arachidonic acid, thereby decreasing the formation of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
50 mg orally once daily
Apply a thin layer to affected skin twice daily. For scalp conditions, use lotion or shampoo as directed.
None Documented
None Documented
Terminal elimination half-life: 24–36 hours, permitting once-daily dosing in chronic therapy
Terminal elimination half-life is approximately 2 hours (range 1.5–3 hours) after topical application; clinical significance: short half-life allows twice-daily dosing.
Renal: ~70% (50% unchanged, 20% as metabolites); Biliary/fecal: ~30%
Primarily renal (about 70% as unchanged drug and metabolites); biliary/fecal elimination of approximately 30%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid